Showing 751-760 of 797 results for "".
- Phase 3 Valbenazine for Chorea in Huntington Disease Completes Enrollmenthttps://practicalneurology.com/news/phase-3-valbenazine-for-chorea-in-huntington-disease-completes-enrollment/2469660/The phase 3 KINECT-HD clinical study (NCT04102579) of valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA) for treatment of chorea in Huntington disease (HD) has completed enrollmen
- Flavonoids May Reduce Risk of Subjective Cognitive Declinehttps://practicalneurology.com/news/flavonoids-may-reduce-risk-of-subjective-cognitive-decline/2469656/A study published in Neurology suggests the risk of cognitive decline may be lowered by as much as 20% with a diet rich in flavonoids. Foods that are high in flavonoids include strawberries, oranges, pepp
- Pimavanserin Effective for Dementia-Related Psychosishttps://practicalneurology.com/news/pimavanserin-effective-for-dementia-related-psychosis/2469641/As published in The New England Journal of Medicine, pimavanserin (Acadia Pharmaceuticals; San Diego, CA) treatment made relapse of dementia related psychosis (DRP) almost 3 times less likely. Results of the phase 3 H
- Phase 3 Study of Tolperisone for Muscle Spasms Reaches 50% Enrollmenthttps://practicalneurology.com/news/phase-3-study-of-tolperisone-for-muscle-spasms-reaches-50-enrollment/2469609/For the phase 3 RESUME-1 clinical study (NCT04671082) of tolperisone (Mydocalm; Neurana Pharmaceuticals, San Diego, CA), 500 of the planned 1,000 participants have enrolled. Tolperisone works as a centrally active muscle relaxant for treatment of acute and painful muscles spasms of the back.
- FDA Approves Pimavanserin Administration by Opening Capsule and Sprinkling Onto Food or Into Liquidhttps://practicalneurology.com/news/fda-approves-pimavanserin-administration-by-opening-capsule-and-sprinkling-onto-food-or-into-liquid/2469448/The Food and Drug Administration (FDA) approved a supplement application to update the pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA) prescription information. This update provides instructions for sprinkling the contents of pimavanserin capsules on food and liquids for dosing and
- Ghrelin Advances to a Phase 2 Trial for Concussion Treatmenthttps://practicalneurology.com/news/ghrelin-advances-to-a-phase-2-trial-for-concussion-treatment/2469406/A phase 2 clinical trial (NCT04558346) of ghrelin (OXE103; Oxeia Biopharmaceuticals, San Diego, CA) for treating concussions has been initiated. The compound being tested is a synthetic form of the end
- FDA Extends Expiration Dating for Diazepam Nasal Sprayhttps://practicalneurology.com/news/fda-extends-expiration-dating-for-diazepam-nasal-spray/2469404/The Food and Drug Administration (FDA) has granted extended expiration dating for diazepam nasal spray (Valtoco; Neurelis, Inc., San Diego, CA). Diazepam was approved by the FDA on January 10, 2020, for the acute treatment of intermittent stereotypic episodes of frequent seizure activity th
- Opicapone Decreases Off Time in Parkinson Diseasehttps://practicalneurology.com/news/opicapone-decreases-off-time-in-parkinson-disease/2469380/Post hoc analyses presented at the Movement Disorder Society's Virtual Congress 2020 September 12-16 showed once-daily opicapone (Ongentys; Neurocrine Biosciences, San Diego, CA) decreased off time’ and increased on time without troublesome dyskinesia in Parkinson disease (PD). Opicapon
- FDA Accepts Supplemental New Drug Application for Pimavanserin for Dementia-Related Psychosis Symptomshttps://practicalneurology.com/news/fda-accepts-supplemental-new-drug-application-for-pimavanserin-for-dementia-related-psychosis-symptoms/2469329/The Food and Drug Administration (FDA) has accepted for filing its supplemental new drug application (sNDA) for pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The sNDA is
- FDA Grants Orphan Drug Designation for Primary Mitochondrial Myopathies Treatmenthttps://practicalneurology.com/news/fda-grants-orphan-drug-designation-for-primary-mitochondrial-myopathies-treatment/2469310/The Food and Drug Administration (FDA) office of orphan products development has granted orphan drug designation to a peroxisome proliferator-activated receptor (PPAR) delta agonist, (REN001; Reneo Pharmaceuticals, San Diego, CA), for the treatment of primary mitochondrial myopathies (PMM).